tailieunhanh - Báo cáo y học: " Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. | Available online http content 1 2 4 R105 Research Prothrombin complex concentrate Beriplex P N in severe bleeding experience in a large tertiary hospital David Bruce and Tim JC Nokes Open Access Department of Haematology Derriford Hospital Brest Road Plymouth Devon PL6 8DH UK Corresponding author Tim JC Nokes Received 7 Apr 2008 Revisions requested 9 May 2008 Revisions received 1 Jul 2008 Accepted 15 Aug 2008 Published 15 Aug 2008 Critical Care 2008 12 R105 doi cc6987 This article is online at http content 12 4 R1 05 2008 Bruce and Nokes licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Major blood loss can often be life-threatening and is most commonly encountered in the settings of surgery and trauma. Patients receiving anticoagulant therapy are also at increased risk of bleeding. We investigated the use of a prothrombin complex concentrate PCC Beriplex P N CSL Behring Marburg Germany to treat severe bleeding in a variety of settings cardiac surgery warfarin therapy and other surgery. Methods Thirty consecutive patients who had received PCC were identified from blood transfusion records. For cardiac surgery and warfarin reversal PCC was administered in accordance with hospital protocols. PCC was administered to cardiac and other surgical patients responding poorly to recognized blood products whereas it was administered first-line to patients with life-threatening bleeds and requiring warfarin reversal in accordance with British Committee for Standards in Haematology guidelines. We conducted a retrospective analysis of patient records in order to ascertain PCC dose use of other blood products and response to PCC clotting screen results before